enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 1. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la empresa
- Sitio web
- engene.com
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede central
- SAINT-LAURENT, Canada
- Consejero delegado
- Mr. Ronald H. W. Cooper
- Empleados
- 81
- Acciones en circulación
- 67.02 M a 2026-09-02
- Capital flotante
- 32.75 M
- Capitalización bursátil
- 132.02 M USD
- Insiders
- 0.11%
- Inversores institucionales
- 84.11%
- Industria (SIC)
- Biological Products, (No Diagnostic Substances)
Descripción
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Bolsas y tickers
| Bolsa | Ticker | Moneda | Precio | Tipo |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.745 -3.06% | acciones ordinarias |
Dividendos
No se han encontrado pagos de dividendos (comprobado el 09.10.2026). Es probable que la empresa no reparta dividendos.
Noticias de esta semana
Aún no hay noticias del sitio web de la empresa.
Principales accionistas
| Titular | Participación | Acciones | Fecha del informe |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 M | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 M | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 M | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 M | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 M | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 M | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 M | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 M | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 M | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 M | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
